Back to companies

Otsuka Holdings Co Ltd: Overview

Otsuka Holdings Co Ltd (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices and OTC products. It markets its products in North America, Europe, and Asia. Otsuka is headquartered in Chiyoda-ku, Tokyo, Japan.

Headquarters Japan

Address 2-9, Kanda Tsukasa-Machi, Chiyoda-Ku, Tokyo, 101-0048


Telephone 81 3 67171410

No of Employees 33,226

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 4578 (TYO)

Revenue (2021) $13.3B 5.3% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -15.3% (2021 vs 2020)

Market Cap* $18.4B

Net Profit Margin (2021) XXX -19.6% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

1,200+

Clinical Trials

Determine Otsuka Holdings Co Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

510+

Catalyst Calendar

Proactively evaluate Otsuka Holdings Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

510+

Consumer Market Data Insights

Insight into market share and brand performance.

300+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Otsuka Holdings Co Ltd’s relevant decision makers and contact details.

220+

Pipeline Drugs

Identify which of Otsuka Holdings Co Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

110+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

110+

Marketed Drugs

Understand Otsuka Holdings Co Ltd’s commercialized product portfolio to stay one step ahead of the market.

60+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

60+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

60+

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

40+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Otsuka Holdings Co Ltd and assess market opportunity for new entrants with patient population 8-year forecasts.

20+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

1

Investigators

Review investigator profiles and find information on trial contacts across Otsuka Holdings Co Ltd, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services Brands
Pharmaceuticals: Transportation Abilify
Anti-psychotic Warehousing Sprycel
Anti-platelet Agents Busulfex
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Contracts/Agreements In September, the company and Sumitomo Dainippon Pharma entered into a collaboration and license agreement for the four psychiatry and neurology compounds.
2021 Others In June, the company has completed introduction of CO2-free electricity at all manufacturing facilities of five subsidiary companies in Japan.
2020 Regulatory Approval In September, the Otsuka group acquired integrated certification for the internationally recognized ISO 14001 Environmental Management System.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Otsuka Holdings Co Ltd Astellas Pharma Inc Daiichi Sankyo Co Ltd Chugai Pharmaceutical Co Ltd Mitsubishi Tanabe Pharma Corp
Headquarters Japan Japan Japan Japan Japan
City Chiyoda-Ku Chuo-Ku Chuo-Ku Chuo-Ku Osaka
State/Province Tokyo Tokyo Tokyo Tokyo Osaka
No. of Employees 33,226 15,455 16,033 7,664 6,728
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Ichiro Otsuka Chairman; Representative Director Executive Board 2015 57
Tatsuo Higuchi Chief Executive Officer; Director; President Executive Board 2008 72
Yuko Makino Director; Chief Financial Officer Executive Board 2019 61
Susumu Tamai Vice Chairman Executive Board - -
Makoto Inoue President; Director Executive Board 2020 64
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer